Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(50.0%)
N/A
2(50.0%)
4Total
Phase 4(2)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04475380Completed

Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents

Role: lead

NCT01674803Not ApplicableCompleted

Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion (BIO-RESORT)

Role: lead

NCT02625493Completed

Patient Preference for Radial Versus Femoral Vascular Access

Role: collaborator

NCT01360918Not ApplicableTerminated

Concomitant Epicardial Pulmonary Vein Isolation in Patients With Atrial Fibrillation Undergoing Elective Cardiac Surgery

Role: collaborator

NCT01331707Phase 4Completed

DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity in an All Comers Population

Role: lead

NCT01066650Phase 4Completed

The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente

Role: lead

All 6 trials loaded